Dr. Pederson on the Importance of Ancestrally-Unbiased Polygenic Risk Assessment in Breast Cancer

Video

Holly Pederson, MD, discusses the importance of ancestrally-unbiased polygenic risk assessment in patients with breast cancer.

Holly Pederson, MD, a staff physician and director of Medical Breast Services in the Breast Center at Cleveland Clinic, discusses the importance of ancestrally-unbiased polygenic risk assessment in patients with breast cancer.

A study examining the polygenic breast cancer risk assessment intended to answer the unmet need of validation in women of non-European descent, according to Pederson. Until recently, most of what was known about genetics and single-nucleotide polymorphisms was derived from research featuring women of European descent, Pederson explains.

However, more data have become available, and were utilized on the study to create a polygenic risk score for all ancestries, she explains. A continental approach was taken gnomically to determine patients' ancestral derivation. This does not involve self-reporting of ancestry, but instead utilizes a genomic breakdown of the 3 continents that contribute most relevantly to women in the US population, including Africa, East Asia, and Europe, Pederson concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH,
Nan Chen, MD
Timothy Yap, MBBS, PhD, FRCP
Parul N Barry, MD,
Erin Frances Cobain, MD
Erin Frances Cobain, MD
Video 6 - "Shared Decision Making and Multidisciplinary Collaboration in the Evolving HR+/HER2- Early-Stage Breast Cancer Landscape"
Manmeet Singh Ahluwalia, MD
Rita Nanda, MD
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"